150 results
Page 3 of 8
8-K
EX-99.1
vi1p3p89d9qw09a1lp
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
6shlovo1j
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
7x83u23w0zd1f
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
bjeqka
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.2
5e26uip
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
q18iqzhmeb3y
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
qc1xh3ne9ij5
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
v40sqb8xg3
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
2evbi4e
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
8gqthjdqhm
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
8-K
EX-99.1
9bc1 nmdjc7t7rwdmaxt
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
opumwimz9nm8
5 May 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
ptc8d
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
peen1qdq39ltop bi
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
k6bt5
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
f3m 39c39a8en7r
2 Mar 20
Other Events
7:05am
S-3ASR
7lav9od0p0rt35
26 Feb 20
Automatic shelf registration
8:35am